CD8A and neoplasm: The efficacy of ICI therapy depends on the intratumoral migration and activation of CD8+ effector T-cells where they perform cytotoxic functions after interaction of the T-cell receptor with tumor-specific peptides displayed on MHC-I complexes on tumor cells (29).